Parecoxib Sodium
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Parecoxib Sodium |
| DrugBank ID | DB08439 |
| Brand Names (EU) | Dynastat |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.55% |
Approved Indication (EMA)
For the short-term treatment of postoperative pain in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine disorder | 99.55% | DL |
| 2 | migraine with brainstem aura | 99.46% | DL |
| 3 | migraine with or without aura, susceptibility to | 99.38% | DL |
| 4 | pulmonary hypertension | 99.09% | DL |
| 5 | headache disorder | 98.90% | DL |
| 6 | kyphoscoliotic heart disease | 98.81% | DL |
| 7 | trigeminal autonomic cephalalgia | 98.68% | DL |
| 8 | atrophoderma vermiculata | 98.64% | DL |
| 9 | rheumatoid arthritis | 98.35% | DL |
| 10 | ulerythema ophryogenesis | 98.33% | DL |
| 11 | benign prostatic hyperplasia (disease) | 98.25% | DL |
| 12 | tendinitis | 97.93% | DL |
| 13 | alopecia | 97.89% | DL |
| 14 | peripheral vascular disease | 97.84% | DL |
| 15 | congenital hypotrichosis milia | 97.79% | DL |
| 16 | fibromyalgia | 97.71% | DL |
| 17 | myositis fibrosa | 97.70% | DL |
| 18 | idiopathic granulomatous myositis | 97.70% | DL |
| 19 | hypotrichosis simplex of the scalp | 97.67% | DL |
| 20 | diffuse alopecia areata | 97.59% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.